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Abstract  
Background and purpose: To determine whether migraine, which has often been described 
as an inaugural manifestation in monogenic cerebrovascular syndromes, is associated with 
cerebral amyloid pathology we assessed migraine and its correlation with MRI markers in 
Hereditary Dutch-type Cerebral Amyloid Angiopathy (D-CAA or HCHWA-D). 
Methods: All D-CAA mutation carriers who visited our clinic between 2012-2018 were 
included. Migraine was diagnosed by an interview and classified according to the 
International Classification of Headache Disorders. MRIs were scored for intracerebral 
hemorrhage (ICH) location(s) and presence of cortical superficial siderosis (cSS). Kaplan 
Meier survival analysis was used for age of ICH onset in carriers with and without migraine. 
Correlation with ICH location(s) and cSS were calculated with Poisson regression analysis 
adjusted for confounders. 
Results: We included 86 D-CAA mutation carriers (57% women, mean age 57 years), 48 
(56%) suffered from migraine, all with aura. Prevalence was higher than expected compared 
with the general population (women p<0.05; men p<0.001). Migraine was the inaugural 
symptom in 77% and an isolated symptom in 35% of the carriers. Carriers with and without 
migraine did not differ for age of first ICH, cSS prevalence or occipital ICH. Time between 
migraine onset and first ICH was 8.5 years. Aura attacks lasting ≥60 minutes signaled acute 
ICH in 55%. 
Conclusions: Migraine with aura is an important, often inaugural symptom in D-CAA. Aura 
attacks lasting ≥60 minutes may signal acute ICH in D-CAA. Migraine with aura may be 
regarded as an early marker of disease in hereditary CAA preceding the occurrence of 
symptomatic ICH by several years.  
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Introduction 
Cerebral amyloid angiopathy (CAA) is an important cause of intracerebral hemorrhage (ICH) 
in elderly.1 CAA patients often report Transient Focal Neurological Episodes (TFNE), which 
are typically recurrent stereotyped attacks that are strongly related with cortical superficial 
siderosis (cSS).2 The definitions of TFNE and migraine aura, described as ‘positive, 
reversible neurological symptoms in a sequential pattern’ according to the International 
Classification of Headache Disorders 3rd edition, overlap.3  
The relationship between migraine and cerebrovascular disease has long been recognized, but 
the underlying pathophysiological basis is still not understood.4, 5 Migraine has been 
described in rare monogenic cerebrovascular syndromes as an early hallmark or even isolated 
symptom, for instance in Cerebral Autosomal Dominant Arteriopathy with Subcortical 
Infarcts and Leukoencephalopathy (CADASIL) and Retinal Vasculopathy with Cerebral 
leukoencephalopathy and Systemic manifestations (RVCL-S), suggesting a link between 
migraine and microvascular changes in early stages of angiopathies.6-8 
Migraine has been reported in CAA, however not much is known about the prevalence and 
characteristics.9 Hereditary Dutch-type Cerebral Amyloid Angiopathy (D-CAA, also called 
Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type, HCHWA-D) is an hereditary 
variant of CAA, caused by a mutation in the Aβ region of the amyloid precursor protein 
(APP) gene. D-CAA patients suffer from recurrent ICH from the age of 50. The 
pathophysiology of D-CAA and sporadic CAA are similar, allowing D-CAA to function as a 
model of CAA, enabling investigation of early disease stages.10-13 
This study investigates migraine prevalence and symptomatology in D-CAA, relating 
migraine history to ICH onset, ICH location and presence of cSS on MRI. 
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Methods 
For this retrospective study we retrieved patient files of all D-CAA mutation carriers who 
visited the Cerebral Hereditary Angiopathy outpatient clinic or the inpatient clinic of our 
neurology department at the Leiden University Medical Center (LUMC), the Dutch national 
referral center for D-CAA, between January 2012 and January 2018. Files were collected in 
August 2018. All available information up to this date was used for the analysis. The 
diagnosis D-CAA carrier was made based on DNA analysis of the Glu693Gln mutation in the 
APP gene, or if no DNA analysis was performed, a medical history with one or more ICHs 
with CAA characteristics according to the Boston criteria on MRI and a positive family 
history for D-CAA.14 In this study, the participants are called ICH carriers if they had at least 
one symptomatic ICH, and non-ICH carriers if they did not have a symptomatic ICH. 
All patients underwent a semi-structured headache questionnaire. Patients who had visited 
our hospital and of whom no information on migraine and headache was available were asked 
to take this structured headache questionnaire via a telephone interview if they had consented 
to be contacted for participation in scientific research before. The questionnaire contained 
questions on migraine and headache characteristics, attack frequency and duration, aura 
characteristics, and age of onset. Furthermore, it contained questions about Transient Focal 
Neurological Episodes (TNFE) and epilepsy. 
The presence, time course and clinical characteristics of migraine were assessed by a 
neurologist or resident in neurology and a final diagnosis was made by a neurologist 
specialized in migraine (G.M.T). Migraine was defined according to the ICHD-3 criteria and 
classified as definite or probable migraine, and the subtypes migraine with aura or migraine 
without aura. Aura without (migraine) headache was also defined according to the ICHD-3 
edition as migraine with aura.3 In addition to migraine history, information on other headache 
subtypes was captured. 
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The dataset analyzed in this study is not publicly available because of restricted access and 
privacy legislation but further information about the dataset is available from the 
corresponding author on reasonable request. Approval for this study has been granted by the 
local ethics review board of the Leiden University Medical Center, who waived the need for 
written informed consent from individual participants for the study. The telephone interviews 
were only conducted in participants who had given previous written informed consent to be 
contacted for participation in scientific research.  
MRI analysis 
All latest available 3 and 1.5 Tesla MRI scans of the brain were retrieved and presence of cSS 
and ICH was scored by two independent observers (E.K. and S.V.). ICH was defined as 
large, irregular areas of signal void which are visible on T1-weighted and T2-weighted 
sequences, according to the STRIVE criteria.15 Location of ICH was classified as occipital or 
non-occipital (frontal, parietal, temporal, infratentorial). We looked at occipital ICH 
specifically since it is known that this lobe is most severely affected with amyloidosis in 
CAA and HCHWA-D.16 cSS was defined as linear hemosiderin deposits within the 
subarachnoid space, leptomeninges and the superficial layers of the cerebral or cerebellar 
cortex.17 One important criterion for the identification of cSS in sporadic CAA is that it 
should be separated from any lobar ICH by at least 3 unaffected sulci.18 However, in D-CAA, 
due to the large number of ICHs in each individual, this makes the identification of cSS 
almost impossible. Therefore, in this study we scored cSS as either ≤3 sulci from an ICH or 
>3 sulci from an ICH, to prevent under recognition of cSS in D-CAA. cSS was scored on 
susceptibility weighted imaging sequences (SWI) or T2*-weighted imaging sequences. In 
case of non-concordance, findings were discussed with a third observer with >15 years of 
experience in the field (M.v.W) in order to achieve consensus. 
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Statistics 
Descriptive statistics were performed. Between carriers with and without migraine, difference 
in proportion of non-ICH mutation carriers and ICH mutation carriers, occipital ICH and cSS 
on MRI was assessed by Poisson regression analysis corrected for age and sex. Interobserver 
variability (kappa value) was calculated for the MRI markers occipital ICH and cSS, the 
grading of interobserver agreement was performed according to the recommendations of 
Landis and Koch.19 Relative risks (RR) with 95% confidence intervals were calculated. The 
difference in age at which the first ICH occurred in mutation carriers with and without 
migraine, as well as in mutation carriers with early and late onset migraine, was assessed with 
a Kaplan Meier survival analysis. Late onset migraine was defined as occurring after the third 
decade, based on earlier studies.20 In order to compare the prevalence of migraine in D-CAA 
to the prevalence in the Dutch population we used data from a large population-based cohort 
study: the Genetic Epidemiology of Migraine (GEM) study.21 Life-time prevalence of 
migraine in D-CAA was calculated separately for men and women. Prevalence of migraine in 
the general Dutch population was calculated by using the age specific life-time prevalence 
tables of the GEM study for men and women separately. We fitted a logistic regression model 
to the combined data with main effects for cohort (D-CAA/general Dutch population) and 
age, and their interaction. We did this for men and women separately. In both models we 
tested for any difference between the cohorts by means of a Chi-square test. 
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Results 
Between January 2012 and January 2018, 95 D-CAA mutation carriers visited the LUMC, all 
of whom were included in this study. Of 19 patients no information on migraine was 
available, ten of these 19 patients had given permission to be contacted for participation in 
scientific research and were contacted and participated in a telephone interview. Of the nine 
remaining patients five were deceased and four patients had not given permission to be 
contacted for participation in research. Of the 86 carriers with a known migraine status the 
mean age was 57 years, 57 (66%) suffered at least one symptomatic ICH, and 49 (57%) were 
women (Table 1). Eight patients were deceased at the time of analysis, for these patients age 
at time of death was used for the age calculation. In 71 carriers the diagnosis D-CAA was 
confirmed by DNA analysis. The remaining 15 carriers had at least one ICH with CAA 
characteristics on MRI in combination with a positive family history of D-CAA. 
 
Migraine symptoms 
Among the 86 carriers with D-CAA and a known migraine status, 48/86 (56%) had a positive 
history of migraine, the majority of whom were women (29/48, 60%). According to the 
ICHD-3 criteria, 39/86 (45%) had definite migraine and 9/86 (10%) probable migraine (Table 
2). All carriers with migraine suffered from the subtype migraine with aura, all reported 
visual aura symptoms, 36/86 (42%) patients had visual auras only, 10/86 (12%) additional 
sensory aura symptoms, and 4/86 (5%) additional aphasia (Table 2). Typical aura without 
headache occurred in 21/86 (24%) of patients, in 12/86 (14%) of patients this was the only 
type of migraine attacks they experienced. Of the carriers, 11/86 (13%) reported both attacks 
with and without aura. The age at onset of migraine with aura showed two peaks; one before 
the third decade and one after the fourth decade (Figure 1). 
Prevalence of migraine in D-CAA was higher for men (p<0.001) and women (p=0.038) 
 8 Koemans 
 
compared with the prevalence in the general Dutch population (also own data from the GEM 
study, which found a lifetime prevalence of migraine of 13% in men and 33% in women).21 
Carriers with migraine were not older than those without migraine, nor was there a difference 
in medical history between the groups (Table 3). The majority of carriers with migraine had 
their first attack before they had the first symptomatic ICH, 37/48 (77%), and for 17/48 
(35%) it was an isolated symptom. The median time between migraine onset and first ICH 
was 8.5 years (range: 3-46). The mean age at which ICH carriers with migraine experienced 
their first ICH did not differ from those without migraine (Figure 2). Mutation carriers with 
an onset of migraine on or before the third decade experienced their first ICH at a 
significantly earlier age compared with mutation carriers with migraine onset after the third 
decade (Figure 3). 
Out of all patients with migraine, 11/48 (23%) had experienced migraine attacks with visual, 
single aura symptomatology lasting over 60 minutes. For 6/11 (55%) of the cases this was 
directly prior to a symptomatic ICH confirmed on the CT scan. For one mutation carrier of 
the six this was the first experienced migraine attack, for five of the carriers this was the first 
time they experienced an ICH. In four of the six carriers the hemorrhage was located in the 
occipital lobe. 
 
Hemorrhage location and cortical superficial siderosis on MRI 
Among the 86 carriers with D-CAA and a known migraine status, for 62 the presence of cSS 
could be scored on 1.5 or 3 Tesla MRI with SWI or T2*-weighted images. cSS was found in 
27/62 (44%) of the carriers, 16/62 (26%) had cSS only ≤3 gyri of ICH, 2/62 (3%) had cSS 
only >3 gyri of ICH, and 9/62 (15%) carriers had cSS both ≤3 gyri and >3 gyri of ICH (Table 
3). The interobserver agreement for cSS was very high (κ =0.91). There was no difference in 
the presence of cSS on MRI for patients with migraine compared to those without migraine 
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(p=0.702, RR 1.17 (95% CI 0.52-2.64)), nor was there a difference if cSS was scored only if 
it was separated from ICH by at least 3 gyri (p=0.361, RR 0.57 (95% CI 0.17-1.92)). As the 
definition of typical aura without headache comes closest to the definition of TFNE, we 
compared cSS occurrence on MRI in patients with typical aura without headache only, to 
patients with migraine headache and patients without migraine and did not find a difference 
(p=0.931, RR 0.95 (95% CI 0.33-2.78)). 
In 70 patients T2 or T1 weighted images were available for analysis of presence and location 
of ICH. Occipital ICH was found in 42/70 (60%) of the patients. The interobserver agreement 
for occipital ICH was substantial (κ =0.83). There was no significant difference in the 
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Discussion 
In this study we found that more than half of D-CAA patients had migraine, 51% of men and 
59% of women, all of them with visual aura. This prevalence is much higher than expected in 
the general population.21-23 Migraine attacks preceded the first symptomatic hemorrhage in 
the majority of carriers but did not seem to be a predictor for an earlier onset of first 
hemorrhage. However, migraine onset on or before the third decade was associated with an 
earlier onset of the first hemorrhage in D-CAA. Single aura symptomatology lasting more 
than 60 minutes occurred in 23% of the patients with migraine, similar to a recent study that 
showed prolonged aura to be quite common in the general population.24 Nevertheless, it was 
an alarming symptom as it was a sign of acute ICH in 55% of our D-CAA carriers with long 
lasting aura. Age of onset of migraine aura in D-CAA occurred in two peaks, with more than 
half of the patients experiencing their first migraine attack after the third decade and a mean 
age of onset which is higher than expected in the general population.25 Migraine with aura 
was not related to occipital ICH or cSS on MRI. We have not found any proof that migraine 
without aura is related to HCHWA-D. 
Beside hemorrhagic events and cognitive decline, TFNEs are a common symptom of CAA. 
TFNEs are defined as ‘recurrent, stereotyped, spreading paraesthesiae or other transient focal 
neurological symptoms (such as weakness, dysphasia) which last several minutes’.26, 27 
TFNEs with visual disturbances are also described in literature, occurring in 14-16% of 
TFNEs.28, 29 The definition of aura in migraine overlaps with that of TFNE, which might raise 
the question whether what is termed as typical migraine aura in D-CAA may also be labelled 
as TFNE. It is, however, not possible to differentiate between the two phenomena based on 
the symptomatology. TFNE is strongly associated with cSS on MRI, whereas in our study 
migraine there was no clear association between the presence of cSS. Although criteria for 
identifying cSS on MRI in sporadic CAA are well known and have been tested multiple 
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times, these criteria are not usable for D-CAA, as due to the large number of ICH in D-CAA, 
cSS is almost always within 3 gyri of an ICH.17, 18 We considered it, therefore, necessary to 
use also an additional scoring system for cSS in D-CAA, in order to avoid under-diagnosis of 
cSS in patients with D-CAA. 
Migraine aura attacks are thought to be a result of cortical spreading depression.30 
Interestingly, migraine with aura is one of the early characteristics of other small vessel 
diseases such as CADASIL and RVCL. In these monogenic angiopathies the migraine 
prevalence is higher than in the general population and an early hallmark of the disease, 
occurring before the first cerebrovascular event.6, 8 Our study in D-CAA shows two peaks in 
age of onset: a first one before the third decade which is comparable to onset of migraine 
with aura in the general population, and a second peak occurring after the fourth decade.31 
Late-life migraine with aura is also found in CADASIL and has been described in sCAA, and 
might be a sign of increasing disease pathology.9, 20 
The high prevalence of migraine with aura in D-CAA might partially be explained by a 
familial clustering of migraine apart from D-CAA. However, the occurrence of visual aura 
attacks as a symptom of a new intracranial hemorrhage and the association of early onset 
migraine to earlier occurrence of first ICH does suggest a link to CAA pathology. The 
presence of migraine in angiopathies such as CADASIL, RVCL and D-CAA suggests that it 
may be caused by vascular changes associated with damage to the intracerebral small vessels 
leading to impaired vasoreactivity and increased susceptibility for cortical spreading 
depression, which has been shown in earlier studies in mouse-models.32 Further studies on 
migraine in hereditary cerebral angiopathies might increase the understanding of migraine 
pathophysiology in general. 
Our study has some limitations. Our study population was relatively small due to the rarity of 
the genetic disease D-CAA. Nevertheless, as D-CAA forms a unique possibility to study the 
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early phases of CAA, research in this relatively small population may provide important 
insights in the pathophysiology of CAA. Another limitation of this study is that some data 
were missing as carriers had passed away. Furthermore, as the data were retrieved 
retrospectively, our data are subjected to recall bias, especially in the D-CAA patients with 
cognitive symptoms. Therefore, we could not reliably investigate migraine trigger factors in 
this population. Lastly, the timing of the MRI images did often not correspond to the onset of 
migraine attacks nor did all carriers get an MRI at the same field strength and around the 
same time, as scans that were made over the years for clinical reasons. Therefore, our results 
concerning the relationship between cSS and ICH should be considered with caution. 
Furthermore, we only investigated the location of ICH and the presence of cSS and did not 
investigate the association between migraine and other CAA markers in detail. 
Our study shows that migraine with aura may be regarded as an early marker of disease in 
hereditary CAA. Further prospective studies are needed to confirm our findings, to determine 
whether migraine with aura is also a frequent symptom in sporadic CAA and to unravel its 
underlying pathophysiology in relation to small vessel damage. 
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Tables and Figures 
Table 1; Demographics and characteristics 
 D-CAA patients* (n=86) 
Mean age in years† (range)  57 (31-84) 
Women (%) 49 (57) 
DNA proven (%) 71 (83) 
Symptomatic ICH (%) 57 (66) 
Mean age at first ICH in years (n=57) (range) 55 (35-78) 




Focal without loss of consciousness 2 (2) 
Focal with loss of consciousness 5 (6) 
Mixed focal and generalized attacks 5 (6) 
Unknown type 1 (1) 
Previous or persisting psychiatric or mood disturbances‡ (%) 35 (41) 
Transient Focal Neurological Episodes (TFNE) (%) 6 (7) 
*D-CAA patients are defined as: 1) DNA proven (positive DNA analysis for codon 693 
mutation in the amyloid-β precursor protein (AβPP) gene) or 2) symptomatic lobar ICH with 
characteristics of CAA on MRI and positive family history, or 3) both. 
†For patients that were deceased at the moment of analysis (n=8) age at time of death was 
used for the calculation. 
‡Including symptoms of depression and anxiety, ADHD, psychosis, PTSS and burn-out. 
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Table 2; Migraine and headache characteristics 
 D-CAA patients (n=86) 
Lifetime prevalence of Migraine (%)* Probable 9 (10) 
Definite 39 (45) 
  In men (n=37) 19 (51) 
  In women (n=49) 29 (59) 
Mean onset age of migraine in years (range)†  37 (9-69) 
Migraine subtypes (%) 
 
Migraine with aura attacks total  48 (56) 
 Migraine with aura only 37 (43) 
Migraine with and without aura‡  11 (13) 
Migraine without aura attacks only 0 (0) 
 Migraine without headache only 12 (14) 
Migraine characteristics (%) 
 
Headache 36 (42) 
 Hemicranial 12 (14) 
 Pulsatile 10 (12) 
Photophobia 23 (27) 
Phonophobia 19 (22) 
Nausea 23 (27) 
Vomiting 12 (14) 
Migraine attack frequency (%) <1 attack/year 9 (10) 
1-4 attacks/year 7 (8) 
5-7 attacks/year 3 (3) 
8-12 attacks/year 9 (10) 
>12 attacks/year 15 (17) 
Unknown 5 (6) 
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Migraine attack duration (%) <1 day 26 (30) 
1-2 days 4 (5) 
3-5 days 6 (7) 
Unknown 12 (14) 
Aura subtypes (%) Visual only 36 (42) 
Visual and sensory only 8 (9) 
Visual and aphasia only 2 (2) 
Visual, sensory and aphasia 2 (2) 
Long lasting aura‡ (%)   11 (13) 
Other headache types (%)  Tension-type headache (TTH) 24 (28) 
 Migraine and TTH 11 (13) 
Medication-overuse headache (MOH) 1 (1) 
 Migraine and MOH 1 (1) 
MOH and TTH 6 (7) 
 Migraine, MOH and TTH 4 (5) 
Unclassifiable  2 (2) 
*Defined according to The International Classification of Headache Disorders, 3rd edition. 
†N=42. Two patients described the onset as ‘during childhood’, these were excluded from the 
calculation. 
‡Defined according to ICHD-3 one single aura symptom lasting >60 minutes. 
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Table 3; Characteristics of D-CAA mutation carriers with migraine compared with D-CAA 





RR (95% CI) 
Mean age in years† (range) 58 (31-84) 57 (35-75)  
Women (%) 29 (60) 20 (53)  
Symptomatic ICH (%) 31 (65) 26 (68) 1.00 (0.59-1.7) 
T1/T2 weighted MRI  (n=40)  (n=30)  
ICH on MRI (%)  32 (80) 22 (73) 1.12 (0.64-1.95) 
 Occipital ICH (%) 25 (63) 17 (57) 1.23 (0.65-2.31) 
SWI/T2*-weighted MRI  (n= 38)  (n=24)  
cSS on MRI (%) 17 (45)    10 (42) 1.17 (0.52-2.64) ‡ 
 cSS >3 gyri separated 
from ICH (%) 
5 (13) 6 (25) 0.57 (0.17-1.92) 
Total number of mutation carriers n=86, for n=16 no T1/T2 weighted MRI data were 
available, for n=24 no SWI/T2* weighted MRI data were available. 
*Certain + probable migraine. 
†For patients that were deceased at the moment of analysis (n=8) age at time of death was 
used for the calculation. 
‡If we compared patients with MA without headache only (n=12): RR 0.95 (0.33-2.78). 
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Figure 1; Age at onset of migraine with aura 
 
N=44, 26 women, 18 men (all with known migraine). Four participants were excluded due to 
unknown age of onset of migraine. Two patients described migraine with aura onset as 
‘during childhood’, these patients were placed in the ≤15 category. 
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Migraine n=31, 31 events, no migraine n=26, 26 events. Mean age at first ICH for patients 
with migraine 54 years (95% CI 51-58), for patients without migraine 56 years (95% CI 53-
59), P=0.749 (Log Rank test). 
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Early onset migraine n=10, 10 events, late onset migraine (onset after the age of 30) n=18, 
18 events. Mean age at first ICH for patients with early onset migraine 49 years (95% CI 47-
51), for patients with late onset migraine 56 years (95% CI 51-60), P=0.024 (Log Rank test). 
